Identifying and overcoming mechanisms of ALK tyrosine kinase inhibitor resistance in lung cancer cells bearing EML4-ALK gene fusions.
Identifying and overcoming mechanisms of ALK tyrosine kinase inhibitor resistance in lung cancer cells bearing EML4-ALK gene fusions.
识别和克服携带 EML4-ALK 基因融合的肺癌细胞中 ALK 酪氨酸激酶抑制剂耐药性的机制。
批准号：
23790906
负责人：
NAGATOMO Izumi
金额：
$2.75万
依托单位：
依托单位国家：
日本
项目类别：
Grant-in-Aid for Young Scientists (B)
财政年份：
2011
资助国家：
日本
项目状态：
已结题
起止时间：
2011 至 2012
中文摘要
翻译
在含有ALK激酶抑制剂（克唑替尼）的培养基中培养EML 4-ALK阳性肺癌细胞（H2228细胞系），并建立克唑替尼耐药细胞。在这些细胞中未检测到ALK激酶编码区的第二突变。通过实时定量RT-PCR分析，在耐药细胞中鉴定了四种长非编码RNA的表达改变。正在对这些改动进行功能分析。
英文摘要
EML4-ALK positive lung cancer cells (H2228 cell line) were cultured in medium containing an ALK kinase inhibitor (Crizotinib), and crizotinib-resistant cells were established. Second mutations within the ALK kinase-codingregion were not detected in those cells. Altered expression of four long non-coding RNAswere identified by real-time quantitative RT-PCR analyses in the resistant cells. Functional analyses of the alterations are in progress.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
